Update on the use of aromatase inhibitors in early-stage breast cancer

Breast Cancer Research

Table 1 Efficacy results of major aromatase inhibitor trials

Trial	AI versus tamoxifen	Strategy	Follow-up, months	DFS HR	DFS Pvalue	OS HR	OS Pvalue
ATAC	Anastrozole	Up-front	100	0.85	0.003	0.97	0.7
BIG	Letrozole	Up-front	76	0.88	0.03	0.87	0.8
BIG	Letrozole-Tamoxifen	Sequencing	71	0.96	NS		NS
BIG	Tamoxifen-Letrozole	Sequencing	71	1.05	NS		NS
TEAM	Examestane	Up-front	33	0.89	0.12		NS
IES	Examestane	Sequencing	55.7	0.76	0.0001		NS
ARNO	Anastrozole	Sequencing	30	0.66	0.049	0.53	0.045
MA-17	Letrozole	Extended	30	0.58	0.001		NS
ABCSG 6a	Anastrozole	Extended	62	0.62	0.031		NS

ABCSG, Austrian Breast & Colorectal Cancer Study Group; AI, aromatase inhibitor; ARNO, Arimidex-Nolvadex; ATAC, Arimidex, Tamoxifen, Alone or in Combination; BIG, Breast International Group; DFS, disease-free survival; HR, hazard ratio; IES, Intergroup Exemestane Study; NS, not significant; OS, overall survival; TEAM, Tamoxifen Exemestane Adjuvant Multinational.

ISSN: 1465-542X